Erratum: Inflammatory processes in cardiovascular disease: a route to targeted therapies

Abstract

Inflammatory processes are firmly established as central to the development and complications of cardiovascular diseases. Elevated levels of inflammatory markers have been shown to be predictive of future cardiovascular events. The specific targeting of these processes in experimental models has been shown to attenuate myocardial and arterial injury, reduce disease progression, and promote healing. However, the translation of these observations and the demonstration of clear efficacy in clinical practice have been disappointing. A major limitation might be that tools currently used to measure 'inflammation' are insufficiently precise and do not provide information about disease site, activity, or discriminate between functionally important activation pathways. The challenge, therefore, is to make measures of inflammation that are more meaningful, and which can guide specific targeted therapies. In this Review, we consider the roles of inflammatory processes in the related pathologies of atherosclerosis and acute myocardial infarction (AMI), by providing an evaluation of the known and emerging inflammatory pathways. We highlight contemporary techniques to characterize and quantify inflammation, and consider how they might be used to guide specific treatments. Finally, we discuss emerging opportunities in the field, including current limitations and challenges that are the focus of ongoing study.Inflammation and its failure to resolve are firmly established as central to the development and complications of several cardiovascular diseases [1][2][3] . Elevated levels of markers of inflammation, such as C-reactive protein (CRP) and serum amyloid A (SAA), have been shown to be predictive of future cardiovascular events across a range of clinical settings [4][5][6] . The role of the innate immune system in the pathogenesis of cardiovascular diseases has been an area of particular focus, with the appreciation that targeting innate immune function Correspondence to R.P.C.: robin.choudhury@cardiov.ox.ac.uk. Author contributionsAll the authors researched data for the article, discussed its contents, and wrote, reviewed, and edited the manuscript before submission. Competing interests statementThe authors declare no competing interests. HHS Public AccessAuthor manuscript Nat Rev Cardiol. Author manuscript; available in PMC 2017 September 01. Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript in experimental models can variously attenuate disease progression and injury, and promote healing [7][8][9][10] .Processes of inflammation contribute to a broad range of cardiovascular diseases; however, in this Review, we consider the roles of inflammatory processes in the related pathologies of atherosclerosis and acute myocardial infarction (AMI), by providing an evaluation of known and emerging inflammatory pathways that are thought to be central to their pathogenesis, and the consequences of their activation. We highlight contemporary techniques to characterize and quantify inflammation, and consider h...

Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review

“…Inflammatory processes play an important role in the development of CVDs and their associated complications (Ruparelia et al, 2017). Atherosclerosis is considered as an inflammatory disease (Ross, 1999).…”

Biomarker assessment for early infarct size estimation in ST-elevation myocardial infarction

“…Inflammatory processes play a pivotal role in the pathogenesis and also in the acute setting of myocardial infarction. Due to myocardial ischaemia, the immune system is activated, locally as well as systemically with a release of different cells and biomarkers detectable in peripheral blood [8]. CRP is one of the most important acute-phase reactant, induced by tissue injury and mediated by hepatic production [30].…”

“…Therefore, more accurate ways of early IS estimation are needed. Above and beyond biomarkers of myocardial necrosis per se, markers of myocardial wall stress (natriuretic peptides) as well as markers of inflammation are correlated with myocardial injury and previous data indicate that even early measurements of such biomarkers can be useful in terms of IS prediction [7][8][9][10]. However, a potential incremental value of admission levels of natriuretic peptides or inflammatory markers over hs-cTnT for IS estimation has never been studied in STEMI patients so far.…”

Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases

“…In recent years, systemic inflammation has been increasingly recognized as a factor crucially involved in modulating cardiac function [8,9]. The connection between inflammation and cardiovascular disease (CVD) has been extensively elucidated in patients with rheumatoid arthritis (RA) and other connective diseases [10,11].…”